MDHAQ/RAPID3 can provide a roadmap or agenda for all rheumatology visits when the entire MDHAQ is completed at all patient visits and reviewed by the doctor before the encounter.
|Abstract:||The management of rheumatoid arthritis (RA) depends more on the patient history than most other chronic diseases. A patient questionnaire provides a uniform, quantitative, protocolized, "scientific" patient history, with documented prognostic significance for work disability and mortality in RA greater than radiographs and laboratory tests and capacity to distinguish active from control treatment in clinical trials and to monitor clinical care with equivalent or greater significance than joint counts or laboratory tests. Therefore, a "scientific" approach to care of a person with a rheumatic disease involves review of patient function, pain, global status, fatigue, RAPID3, review of systems, self-report joint count, and recent medical history on an MDHAQ before conversation with the patient. This practice may be viewed as analogous to a doctor reviewing blood pressure, hemoglobin A1c, viral load, or radiograph before meeting with a patient who has hypertension, diabetes, HIV, or a healing fracture to provide a roadmap or agenda for the visit. Some sites have implemented RAPID3 without the remainder of MDHAQ, a practice that is discouraged. The MDHAQ requires only 5 to 10 minutes of the patient's time and involves a single sheet of paper, which is needed for a simple RAPID3, or even a patient global estimate of status to score a DAS28 or CDAI. Completion of MDHAQ/RAPID3 by each patient at each visit in the infrastructure of care with review by the doctor helps prepare the patient for the visit, improves doctor-patient communication, saves time for the doctor, and provides a roadmap or agenda for the visit.|
Physicians (Health aspects)
Hypertension (Health aspects)
HIV (Viruses) (Health aspects)
Antirheumatic agents (Health aspects)
Rheumatoid arthritis (Health aspects)
Skummer, Philip T.
Grisanti, Michael T.
|Publication:||Name: Bulletin of the NYU Hospital for Joint Diseases Publisher: J. Michael Ryan Publishing Co. Audience: Academic Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2012 J. Michael Ryan Publishing Co. ISSN: 1936-9719|
|Issue:||Date: July, 2012 Source Volume: 70 Source Issue: 3|
|Product:||Product Code: 8011000 Physicians & Surgeons NAICS Code: 621111 Offices of Physicians (except Mental Health Specialists)|
A doctor who treats a patient with hypertension generally knows the
blood pressure before discussion with the patient. A doctor who treats a
patient with diabetes generally knows the hemoglobin A1c before
discussion with the patient. A doctor who treats a patient with HIV
generally knows the viral load before discussion with the patient. A
doctor who treats a patient with a fracture generally examines the
radiograph before discussion with the patient. All these doctors are
implementing a "scientific" approach to patient care by having
relevant quantitative data available to inform the discussion with the
The management of rheumatoid arthritis (RA) depends more on the patient history than most other chronic diseases, (1) and similar considerations pertain to most rheumatic diseases. A patient questionnaire may be regarded as providing a "scientific" patient history, which meets the same criteria for the scientific method seen for laboratory tests: quantitative data in a standard, protocolized format, with criteria for interpretation in prognosis and management decisions. Indeed, patient questionnaire scores for physical function are more significant than laboratory tests, radiographs, or any high-technology data in the prognosis of severe outcomes of RA such as work disability (2-6) and premature mortality. (7-12) Patient questionnaire scores are as effective as joint counts and laboratory tests to distinguish active from control treatments in clinical trials (13) and to document changes in clinical status in usual care.
Therefore, a "scientific" approach to care of a person with RA (or any rheumatic disease) should include awareness of patient questionnaire data before conversation with the patient, as discussed in previous essays in this journal (13-15) concerning the MDHAQ (multidimensional health assessment questionnaire) (16,17) (Fig. 1) and RAPID3 (routine assessment of patient index data), (18,19) an index of patient-reported measures. Of course, doctor-patient conversation is required to clarify questionnaire data and elicit further information for an optimal patient history. Nonetheless, quantitative scores and other questionnaire information provide important initial components of an accurate history.
[FIGURE 1 OMITTED]
[FIGURE 2 OMITTED]
The MDHAQ (16,17) (Fig. 1) includes physical function, pain, and global estimate of status, the three RA Core Data Set (20) patient-reported measures. Templates to score these measures and RAPID3 (an index of these three measure) are provided, facilitating calculation of RAPID3 in about 5 seconds. (19) The MDHAQ also queries fatigue, self-report rheumatoid arthritis disease activity index (RADAI) joint count, (21) and number of symptoms on a review of systems, as well as recent medical history, to inform discussion with the patient. All this information is available on two sides of a single sheet of paper. Just as a roadmap enhances travel to an unknown place or an agenda provides structure to any meeting, MDHAQ/RAPID3 may be viewed as a "roadmap" or "agenda" for a doctor to help direct a patient encounter. A brief review of the roadmap or agenda can provide information to improve effective use of time.
RAPID3 scores are correlated significantly with DAS28 (disease activity score with 28 joint count) and CDAI (clinical disease activity index) scores in clinical trials of adalimumab, (22) abatacept (23,24) and certolizumab (25) (Fig. 2), and in usual clinical care (18,19) (Fig. 2). RAPID3 categories for high, moderate, low severity and remission are similar to categories for DAS28 and CDAI scores, (18,19,24,25) as targets for a treat-to-target strategy for RA. (26-28) Scoring of RAPID3 requires 5 seconds, compared to 90 to 94 seconds for a formal joint count and up to 2 minutes for a DAS28 or CDAI. (19) Physical function scores on MDHAQ and other questionnaires are far more significant than radiographs or laboratory tests in the prognosis of severe outcomes in RA, including work disability (2-6) and premature mortality. (7-12) MDHAQ/RAPID3 is informative in all rheumatic diseases to document changes in patient status. (29)
Over the last decade, MDHAQ/RAPID3 has been used by an increasing number of rheumatologists. A recent American College of Rheumatology (ACR) survey indicated that 29% of respondents used RAPID3, compared to 28% for DAS28 and 15% for CDAI. (30) Some centers have incorporated MDHAQ into the infrastructure of care but have deleted most or all of other components of the MDHAQ, retaining only RAPID3. This practice appears undesirable for several reasons (14):
1. The MDHAQ requires only 5 to 10 minutes of the patient's time. Almost all patients wait at least 5 to 10 minutes before seeing a doctor. Patients have more than enough time to complete an MDHAQ with a self-report joint count, review of systems, and recent medical history, beyond a simple RAPID3 score.
2. Completion of an entire MDHAQ in the waiting area helps the patient prepare for the visit, particularly the self-report joint count, review of systems, and recent medical history, which are not included in RAPID3.
3. The self-report joint count, review of systems, and recent medical history, in addition to RAPID3, save time for the doctor when reviewed prior to seeing the patient; a 10 to 15 second review may give information that otherwise requires 10 to 15 minutes of conversation between doctor and patient. The time saved improves the quality of the visit, to include other measures and conversation about matters directly relevant to the patient and doctor. (14)
4. Any abbreviated version of MDHAQ including only RAPID3 requires a single piece of paper, no less than an entire MDHAQ, which occupies two sides of one sheet of paper (or can be administered electronically). If MDHAQ requires no more paper than RAPID3, and patients have time to complete MDHAQ, why not obtain the additional information?
5. A patient global estimate of status is required to score a DAS28 or CDAI. This patient global estimate is collected from the patient on a piece of paper, which ironically could just as easily involve an MDHAQ on a single sheet of paper.
6. Collection of MDHAQ/RAPID3 in no way prevents a doctor from performing a formal joint count, scoring a DAS28, (31) CDAI, (32) SDAI (Simplified Disease Activity Index), (32) ultrasound, or any other measure that is regarded as desirable for clinical care. Indeed, as noted above, more time is available for a joint count, conversation that is more relevant to the patient and doctor, or other activities, as a result of saving time using the MDHAQ.
Three steps in optimal implementation of MDHAQ/ RAPID3 or any patient self-report questionnaire in usual care are described:
1. Each patient is given a questionnaire by the receptionist upon registration for each visit to complete in the waiting area before seeing the physician, to help prepare the patient for the encounter.
2. The physician reviews the questionnaire before seeing the patient to provide a "scientific" roadmap or agenda. This brief review reinforces to the patient the importance of the questionnaire and saves time for the doctor by having much factual information available before seeing the patient.
3. Scores on the MDHAQ for physical function, pain, global estimate, fatigue, RAPID3, and number of symptoms are entered into a flowsheet that also includes laboratory tests and medications; the flowsheet may be constructed with pencil and paper or electronically. The value of MDHAQ and other information is considerably enhanced when it can be compared conveniently at a glance over time to previous visits.
Each Patient Completes an MDHAQ/RAPID3 at Each Visit
It is quite simple for the office receptionist to give an MDHAQ/RAPID3 to each patient upon registration for each visit. In almost all successful settings, an identical questionnaire is given to each patient regardless of diagnosis, although a different version may be given to new versus "return" patients. MDHAQ helps prepare the patient for the encounter by focusing on concerns to discuss with the doctor. A patient seen in a rheumatology setting a week after a previous visit--an unusual occurrence--might suggest that she or he does not need to complete a questionnaire, as one was completed the previous week. The appropriate response is that if there is any reason for the doctor to see the patient, there is a reason to document whether scores and other information on the MDHAQ have changed.
Completion of an MDHAQ by the patient does not disrupt office flow or require any extra time and effort from the doctor, if each patient is given the questionnaire by the receptionist at each visit in the infrastructure of office practice. As noted, availability of an MDHAQ does not in any way inhibit a doctor from as much conversation as appears appropriate, performance of a formal joint count, or scoring a DAS28 or CDAI that requires a joint count. Indeed, as noted, availability of factual information allows more conversation and time for a formal joint count and other measures.
Review of MDHAQ by Rheumatologist.
MDHAQ provides information for the doctor, including RAPID3, the self-report joint count, review of systems, and recent medical history, in 10 to 15 seconds that would require 10 to 15 minutes of conversation to document in the medical record, an obvious potential time-saving strategy. Many doctors' offices ask patients to complete some type of patient self-report questionnaire before seeing a doctor. In most settings, the doctor may review the patient's responses on the questionnaire, sometimes prior to seeing the patient. However, review of the questionnaire generally does not involve the type of systematic approach that characterizes review of laboratory tests, radiographs, cardiograms, or other information from high-technology sources. (33,34)
A traditional perspective in clinical medicine is that information from a patient history is "subjective," in contrast to "objective" information from the laboratory, imaging studies, biopsies, and other high-technology sources. The literal meaning of the term "subjective" is that the source of information is the person herself or himself, in contrast to "objective" information from a source outside of the self. However, the term "subjective" applied to medical information often is interpreted to imply "poorly reliable" and "unscientific," in contrast to "scientific," "objective" high-technology data. This is ironic, in a sense, since several studies suggest that the patient history often is the most important information for diagnosis and management. (35-38)
[FIGURE 3 OMITTED]
The value of the patient history is particularly seen in rheumatic diseases in which an objective high-technology "gold standard" measure is not available for all individual patients. (1,39) Nonetheless, many doctors find it difficult to accept information from a patient as "scientific," based on a paradigm that high-technology "objective" data are more valuable than self-report "subjective" data. Of course, the doctor knows much more than the patient about pathophysiology and treatment of disease. However, the patient is the "expert" concerning her or his capacity to turn on faucets or perform other activities, pain, global status, fatigue, which joints are painful, and even recent medical history.
Patient questionnaire scores are more reproducible than joint counts or radiographic scores and do not require the same examiner at each assessment. Data concerning factual information from a single observer (the patient) are almost always more reproducible than data requiring interaction of a doctor with a patient, as a joint count.
A number of additional concerns have been advanced by doctors regarding MDHAQ/RAPID3 in routine care. Many doctors are uncomfortable about educating and training their staff in procedures in which they have no experience from medical school, residency, or fellowship training. There is a general discomfort with novelty, particularly changes of office procedure with no incremental reimbursement. Some concerns and misconceptions related by various rheumatologists are summarized in Table 1. The reader is invited to review the Table to identify his or her own concerns to analyze possible reasons not to implement MDHAQ/RAPID3 and to contact the senior author (TP) about additional concerns.
One matter that may be confusing involves the difference between a standard measure and information that may be important in clinical care beyond the standard measure. For example, a 28 joint count excludes 42 joints from the earlier 70 joint count, including the metatarsal phalangeal joints of the feet, acromioclavicular joints, and others. (40) The 28 joint count was introduced because most excluded joints are far less frequently involved than included joints, and abnormal findings in the feet may be poorly correlated with disease activity. (40) Exclusion of non-essential joints saves considerable time, without loss of capacity to distinguish active from control treatment in clinical trials (41) or to monitor patients in clinical care. However, a careful joint examination should include all joints, particularly joints for which a patient notes symptoms, although these joints are not included in a formal joint count.
Similarly, scoring of RAPID3 in no way suggests that a formal joint count or careful joint examination is not an important component of an encounter for a patient with RA--indeed, a joint examination must be performed to adequately interpret RAPID3 scores. Furthermore, scoring of RAPID3 does not preclude a formal joint count or formal physician global estimate of status. Of note, earlier studies of indices termed RAPID4 and RAPID5 included a joint count or physician global estimate or both added to RAPID3.18,23 However, extensive statistical analyses indicated that a formal joint count and physician global score add little to change RAPID3 (18,23) and increased the time required to score an index from 5 seconds up to 20 to 25 seconds--a meaningful change in busy clinical settings. The authors advocate a careful joint examination and a quantitative physician global score at each visit of patients with RA. Exclusion of a measure from a formal index does not mean that excluded information may not be very important and even critical for patient care.
Flowsheets for Clinical Care
Any quantitative measure--whether a laboratory test, MDHAQ/RAPID3, or joint count--is considerably more valuable in the care of a patient with a chronic disease if the data from the previous visit are also available for comparison conveniently at a glance on a flowsheet at the time of the clinical decision. Optimal use of MDHAQ/RAPID3 scores includes a simple flowsheet, which also should include the most pertinent laboratory test results and medications. The use of such flowsheets is standard practice in certain types of clinical subspecialties such as oncology but has not been adopted by many rheumatologists.
A rheumatology flowsheet traditionally has been maintained in simple pencil and paper, which may appear unfashionable at this time in many settings in this era of the electronic medical record (EMR). The senior investigator maintained paper flowsheets during the 1980s and 1990s, which involved an extra 15 to 30 seconds, but easily, saved that time in not having to "flip" through many pages of a paper medical record. Even reviewing many screens in an electronic record is considerably more time-consuming than glancing at a simple paper or electronic flowsheet, although many rheumatologists will not make this effort if they have an installed EMR.
Therefore, a major issue for rheumatology practice at this time is to introduce patient questionnaire scores into flowsheets on an EMR. This is not difficult computer science if a flowsheet exists for laboratory data since patient questionnaire scores are quantitative variables no different from laboratory test results. Some rheumatologists also have tried to incorporate automatic scoring by entering the scores for physical function, pain, and global estimate of status directly into an EMR to compute a RAPID3 score. This may appear desirable if the entry is performed by an assistant, but is not critical since a RAPID3 score can be calculated by a rheumatologist or anyone else in about 5 seconds--more "rapid" than viewing a score on a computer.
The authors suggest including a RAPID3 score and perhaps fatigue score and number of symptoms on a paper or EMR flowsheet. It may appear somewhat incongruous to advocate collection of the entire MDHAQ rather than a simple RAPID3 score, when only RAPID3 and a few other scores are included on the flowsheet. However, the additional queries concerning the self-report joint count, review of systems, and recent medical history save time for the doctor by simple visual review over a few seconds to recognize pertinent positive and negative information from a patient history. For example, a patient experiencing a flare of RA may report a recent infection or family stress, which is very important information, but not incorporated into a flowsheet.
An example of a flowsheet is presented for a patient with RA (Fig. 3). Other examples in other rheumatic diseases are illustrated in previous reviews. (41)
MDHAQ/RAPID3 at every visit can improve doctor-patient communication with minimal effort on the part of the doctor. RAPID3 scores are comparable to DAS28 and CDAI scores in 5 seconds rather than 2 minutes to facilitate a treat-to-target strategy. MDHAQ/RAPID3 self-report joint count, review of systems, and recent medical history help prepare the patient for the visit, improve doctor-patient communication, and save time for the doctor--providing in 10 to 15 seconds information that may require 10 to 15 minutes to elicit in conversation--when reviewed before the encounter. The data are considerably more valuable when charted in flowsheets that also include laboratory tests and medications. The reader is invited to contact the senior investigator at email@example.com regarding questions and further information concerning MDHAQ/RAPID.
Dr. Pincus/Health Report Services, Inc. holds copyright on MDHAQ/RAPID3. No license is needed for clinicians who may freely use MDHAQ/RAPID3 to monitor patient status in usual clinical care. Royalties are received for license fees from for-profit pharmaceutical and electronic medical record companies for use of MDHAQ/RAPID3. The other authors have no financial or proprietary interest in the subject matter or materials discussed, including, but not limited to, employment, consultancies, stock ownership, honoraria, and paid expert testimony.
(1.) Castrejon I, McCollum L, Durusu Tanriover M, Pincus T. Importance of patient history and physical examination in rheumatoid arthritis compared to other chronic diseases: Results of a physician survey. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1250-5.
(2.) Callahan LF, Bloch DA, Pincus T. Identification of work disability in rheumatoid arthritis: Physical, radiographic and laboratory variables do not add explanatory power to demographic and functional variables. J Clin Epidemiol. 1992 Feb;45(2):127-38.
(3.) Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients. J Rheumatol. 1998 Nov;25(11):2108-17.
(4.) Fex E, Larsson B, Nived K, Eberhardt K. Effect of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J Rheumatol. 1998 Jan;25(1):44-50.
(5.) Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol. 1999 Aug;26 (8):1681-5.
(6.) Barrett EM, Scott DGI, Wiles NJ, Symmons DPM. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology. 2000 Dec;39(12):1403-9.
(7.) Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984 Aug;27(8):864-72.
(8.) Wolfe F, Kleinheksel SM, Cathey MA, et al. The clinical value of the Stanford health assessment questionnaire functional disability Index in patients with rheumatoid arthritis. J Rheumatol. 1988 Oct;15 (10):1480-8.
(9.) Leigh JP, Fries JF. Mortality predictors among 263 patients with rheumatoid arthritis. J Rheumatol. 1991 Sep;18(19):1307-12.
(10.) Maiden N, Capell HA, Madhok R, et al. Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients? Ann Rheum Dis. 1999 Sep;58(9):525-9.
(11.) Sokka T, Hakkinen A, Krishnan E, Hannonen P. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis. 2004 May;63(5):494-7.
(12.) Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008 Sep-Oct;26(5 Suppl 51):S35-61.
(13.) Pincus T, Bergman MJ, Yazici Y. RAPID3-an index of physical function, pain, and global status as "vital signs" to improve care for people with chronic rheumatic diseases. Bull NYU Hosp Jt Dis. 2009;67(2):211-25.
(14.) Pincus T, Yazici Y, Bergman MJ. Beyond RAPID3 - practical use of the MDHAQ to improve doctor-patient communication. Bull NYU Hosp Jt Dis. 2010;68(3):223-31.
(15.) Pincus T. Are patient questionnaire scores as "scientific" as laboratory tests for rheumatology clinical care? Bull NYU Hosp Jt Dis. 2010;68(2):130-9.
(16.) Pincus T, Swearingen C, Wolfe F. Toward a multidimensional health assessment questionnaire (MDHAQ): Assessment of advanced activities of daily living and psychological status in the patient friendly health assessment questionnaire format. Arthritis Rheum. 1999 Oct;42(10):2220-30.
(17.) Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a multidimensional health assessment questionnaire for standard care of patients with rheumatic diseases. J Rheumatol. 2005 Aug;32(8):1432-9.
(18.) Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (routine assessment of patient index data 3), a rheumatoid arthritis index without formal joint counts for routine care: Proposed severity categories compared to DAS and CDAI categories. J Rheumatol. 2008 Nov;35(11):2136-47.
(19.) Pincus T, Swearingen CJ, Bergman MJ, et al. RAPID3 on an MDHAQ is correlated significantly with activity levels of DAS28 and CDAI, but scored in 5 versus more than 90 seconds. Arthritis Care Res (Hoboken). 2010 Feb;62(2):181-9.
(20.) Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 1993 Jun;36(6):729-40.
(21.) Stucki G, Liang MH, Stucki S, et al. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Arthritis Rheum. 1995 Jun;38(6):795-8.
(22.) Pincus T, Chung C, Segurado OG, et al. An index of patient self-reported outcomes (PRO Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol. 2006 Nov;33(11):2146-52.
(23.) Pincus T, Bergman MJ, Yazici Y, et al. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford). 2008 Mar;47(3):345-9.
(24.) Pincus T, Hines P, Bergman MJ, et al. Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials. J Rheumatol. 2011 Dec;38(12):2565-71.
(25.) Pincus T, Furer V, Keystone E, et al. RAPID3 (routine assessment of patient index data) severity categories and response criteria: Similar results to DAS28 and CDAI in the RAPID1 (rheumatoid arthritis prevention of structural damage) clinical trial of certolizumab pegol (CZP). Arthritis Care Res (Hobo ken). 2011 Aug;63(8):1142-9.
(26.) Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet. 2009 Aug 8;374(9688):430-2.
(27.) Pincus T. Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care? Bull NYU Hosp Jt Dis. 2009;67(3):254-66.
(28.) Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010(Apr); 69(4):631-7.
(29.) Pincus T, Askanase AD, Swearingen CJ. A multi-dimensional health assessment questionnaire (MDHAQ) and routine assessment of patient index data (RAPID3) scores are informative in patients with all rheumatic diseases. Rheum Dis Clin North Am. 2009 Nov;35(4):819-27, x.
(30.) Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012 May;64(5):640-7.
(31.) Prevoo MLL, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995 Jan;38(1):44-8.
(32.) Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S100-8.
(33.) Weed LL. Medical records that guide and teach. N Engl J Med. 1968 Mar 14;278(11):593-600.
(34.) Weed LL. Medical records that guide and teach. N Engl J Med. 1968 Mar 21;278(12):652-57 concl.
(34.) Hampton JR, Harrison MJG, Mitchell JRA, et al. Relative contributions of history-taking, physical examination, and laboratory investigation to diagnosis and management of medical outpatients. Br Med J. 1975 May 31;2(5969):486-9.
(35.) Sandler G. The importance of the history in the medical clinic and the cost of unnecessary tests. Am Heart J. 1980 Dec;100(6 Pt 1):928-31.
(36.) Peterson MC, Holbrook JH, Hales DV, et al. Contributions of the history, physical examination, and laboratory investigation in marking medical diagnoses. West J Med. 1992 Feb;56 (2):163-5.
(37.) Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med. 1993 Jan 15;118(2):81-90.
(38.) Pincus T, Yazici Y, Sokka T. Complexities in assessment of rheumatoid arthritis: absence of a single gold standard measure. Rheum Dis Clin North Am. 2009 Nov;35(4):687-97, v.
(39.) Fuchs HA, Brooks RH, Callahan LF, Pincus T. A simplified twenty-eight joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum. 1989 May;32(5):531-7.
(40.) Fuchs HA, Pincus T. Reduced joint counts in controlled clinical trials in rheumatoid arthritis. Arthritis Rheum. 1994 Apr;37(4):470-5.
(41.) Pincus T, Mandelin AM 2nd, Swearingen CJ. Flowsheets that include MDHAQ physical function, pain, global, and RAPID3 scores, laboratory tests, and medications to monitor patients with all rheumatic diseases: an electronic database for an electronic medical record. Rheum Dis Clin North Am. 2009 Nov;35(4):829-42, x-xi.
Theodore Pincus, M.D., Isabel Castrejon, M.D., and Yusuf Yazici, M.D., are from the Department of Medicine, Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, New York. Philip T. Skummer is from Cornell University, Ithaca, New York. Michael T. Grisanti is from Canisius College, Buffalo, New York.
Correspondence: Theodore Pincus, M.D., Division of Rheumatology, NYU Hospital for Joint Diseases, 301 East 17th Street, Room 1608, New York, New York 10003; firstname.lastname@example.org.
Table 1 Concerns and Misconceptions of Many Rheumatologists Regarding MDHAQ/RAPID3 Concerns/Misconceptions about MDHAQ/RAPID3 Correct Understanding of MDHAQ/RAPID3 A. Concerns/misconceptions about information from MDHAQ/RAPID3 1 "I can tell when my patient Although questionnaire is better, so I don't need a responses usually confirm formal questionnaire." clinical impressions, discordance between patient and physician global estimates of status is common. 2 "I can get all the Data from clinical trials information I need about apply to groups, not therapies from clinical necessarily to individuals, trials." who very in responses over a wide range that should be recognized. 3 "I don't want a patient A patient questionnaire never questionnaire to replace replaces examining the examining the patient." patient. 4 "I don't want a patient A patient questionnaire never questionnaire to interfere replaces conversation with with doctor-patient the patient and enhances communication and replace doctor-patient communication conversation." by preparing the patient and doctor for the encounter. 5 "I want to take the patient The history must be taken by history--not get it from a the doctor--the questionnaire patient questionnaire." saves time for the doctor when reviewed before seeing the patient by providing factual information and many pertinent negatives. 6 "RAPID3 responses should not No measure or index alone, be used to trigger automatic whether a laboratory test, therapeutic decisions." radiograph, DAS28, CDAI, RAPID3, etc., triggers therapeutic decisions--all decisions are based on a synthesis of all available information by the doctor. B. Concerns/misconceptions about MDHAQ/RAPID3 in office practice 1 "Patient questionnaires add No evidence for this if extra time and interfere with questionnaire distributed by patient flow." the receptionist to each patient at each visit. 2 "Many patients will object to Of course, some people completing questionnaires." complain about anything that involves effort; when patients see that MDHAQ/ RAPID3 is important in their care, they accept it, and many appreciate its value. 3 "Patient questionnaire should This idea may sound good but be used only at certain is impossible to implement intervals rather than at each for the clinic receptionist; visit." furthermore, data should be available at the time of change in medication to determine change in status; if there is a reason to see the patient, an MDHAQ/RAPID3 should be completed. 4 "An MDHAQ cannot be completed Of course, some patients have by patients of low education difficulty completing level." questionnaires, but even most illiterate patients usually have a "literacy partner" to help them simply to get to the clinic, who can help complete the questionnaire. 5 "Electronic data capture is Use of paper is generally far invariably more effective less expensive, as easy for than pencil and paper." patients to complete, and much easier to transfer information from patient to doctor at this time. C. Concerns/misconceptions about self-report versus traditional measures 1 "Patient questionnaire data Actually, patient don't give me as good questionnaires are more information to guide clinical sensitive to change than decisions and prognosis as laboratory tests or joint traditional radiographic or counts in most patients and laboratory measures." more significant in prognosis. 2 "How can I monitor a patient A careful joint examination quantitatively without a may be sufficient--it matters joint count?" a lot whether a patient has 2 vs. 12 swollen joints, which can be ascertained in 5 seconds, but not necessarily whether 1 vs. 2 or 11 vs. 12, which requires about 2 minutes to determine. 3 "Patient questionnaire scores All measures in patients with are influenced by RA are less likely to change irreversible damage, so they in patients who have are not sensitive to control irreversible damage, of inflammation, unlike joint including joint counts and counts." questionnaires. 4 "I don't want an index that One should distinguish does not include a doctor between a measure and a measure." decision; a decision is always made by a doctor on the basis of all information, which may be improved by available measures, none of which alone dictates a decision.
|Gale Copyright:||Copyright 2012 Gale, Cengage Learning. All rights reserved.|